Celyad Oncology SA
CYADDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Injection of C3BS-CQR-1
Heart Failure
C-Cure
Heart Failure Class II or III
NKR-2
AML
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Injection of C3BS-CQR-1 | Phase 3 | Heart Failure | - | - |
C-Cure | Phase 3 | Heart Failure Class II or III | - | - |
NKR-2 | Phase 2 | AML | - | - |
Heart Failure
1 drug in this indication
Heart Failure Class II or III
1 drug in this indication
AML
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Celyad Oncology SA's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Celyad Oncology SA's (CYAD) pipeline across Phase 3, Phase 2. Its lead program is Injection of C3BS-CQR-1 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Celyad Oncology SA's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Celyad Oncology SA (CYAD) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CYAD biotech catalysts?→
Add CYAD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Celyad Oncology SA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.